Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001
Sponsor: Haya Therapeutics, Inc.
Summary
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of HTX-001 in human adult participants.
Official title: A Two-Part, Phase 1, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and WISPER Target Engagement of HTX-001 in Adult Healthy Participants (Part 1) and in Adult Participants With Nonobstructive Hypertrophic Cardiomyopathy (Part 2)
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2026-10
Completion Date
2027-03
Last Updated
2026-10-27
Healthy Volunteers
Yes
Interventions
HTX-001
HTX-001 is an investigational antisense oligonucleotide (ASO)
Locations (3)
Lahey Clinic
Boston, Massachusetts, United States
Saint Luke's Health System
Kansas City, Missouri, United States
The Lindner Research Center at The Christ Hospital
Cincinnati, Ohio, United States